Compare Stocks: OPT, KOD, AGIO, and VCEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$32.58 -1.0%	$33.81	$22.24 ▼ $46.00	$1.95B	0.6	880,657 shs	740,409 shs
KOD Kodiak Sciences	$32.35 -2.6%	$38.31	$10.94 ▼ $47.84	$2.03B	2.18	744,146 shs	2.17 million shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
VCEL Vericel	$39.71 +1.0%	$42.56	$28.95 ▼ $49.32	$2.03B	1.04	479,084 shs	359,339 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-1.48%	-4.96%	-14.04%	-12.70%
KOD Kodiak Sciences	0.00%	-1.10%	-17.31%	-9.99%	+108.84%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
VCEL Vericel	0.00%	-0.77%	-3.57%	-14.10%	+31.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$32.58 -1.0%	$33.81	$22.24 ▼ $46.00	$1.95B	0.6	880,657 shs	740,409 shs
KOD Kodiak Sciences	$32.35 -2.6%	$38.31	$10.94 ▼ $47.84	$2.03B	2.18	744,146 shs	2.17 million shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
VCEL Vericel	$39.71 +1.0%	$42.56	$28.95 ▼ $49.32	$2.03B	1.04	479,084 shs	359,339 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-1.48%	-4.96%	-14.04%	-12.70%
KOD Kodiak Sciences	0.00%	-1.10%	-17.31%	-9.99%	+108.84%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
VCEL Vericel	0.00%	-0.77%	-3.57%	-14.10%	+31.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.75	28.15% Upside
KOD Kodiak Sciences	2.57	Moderate Buy	$56.83	75.68% Upside
OPT Opthea	1.00	Sell	N/A	N/A
VCEL Vericel	2.67	Moderate Buy	$58.40	47.07% Upside

Current Analyst Ratings Breakdown

Latest OPT, KOD, AGIO, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
9/24/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
9/21/2026	AGIO Agios Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/21/2026	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $50.00
9/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
8/24/2026	AGIO Agios Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
8/7/2026	AGIO Agios Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$31.00 ➝ $34.00
8/3/2026	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $66.00
7/31/2026	VCEL Vericel	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
7/31/2026	VCEL Vericel	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $58.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	36.00	N/A	N/A	$20.46 per share	1.59
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
OPT Opthea	$25K	20,993.46	N/A	N/A	($1.31) per share	-2.60
VCEL Vericel	$306.30M	6.64	$0.56 per share	71.49	$7.01 per share	5.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
OPT Opthea	-$162.79M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	$16.52M	$0.47	84.49	47.27	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)

Latest OPT, KOD, AGIO, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
KOD Kodiak Sciences	N/A	2.49	2.49
OPT Opthea	N/A	0.22	0.22
VCEL Vericel	N/A	5.04	4.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
KOD Kodiak Sciences	89.06%
OPT Opthea	55.95%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
KOD Kodiak Sciences	44.40%
OPT Opthea	3.20%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
OPT Opthea	8	153.91 million	165.53 million	Not Optionable
VCEL Vericel	398	51.21 million	47.32 million	Optionable

OPT, KOD, AGIO, and VCEL Headlines

Recent News About These Companies

Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain

September 26 at 11:11 PM | finance.yahoo.com

Vericel Corporation (NASDAQ:VCEL) Stock Has Average Price Target of $58.40

September 25 at 6:13 AM | marketbeat.com

Bank of America Corp DE Invests $45.21 Million in Vericel Corporation $VCEL

September 22, 2026 | marketbeat.com

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

September 14, 2026 | seekingalpha.com

Vericel Corporation $VCEL Shares Sold by Wellington Management Group LLP

September 12, 2026 | marketbeat.com

Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL

September 10, 2026 | marketbeat.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

September 8, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Vericel Corporation $VCEL

September 5, 2026 | marketbeat.com

115,630 Shares in Vericel Corporation $VCEL Bought by Legal & General Group Plc

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Vericel Corporation $VCEL

September 2, 2026 | marketbeat.com

Jupiter Topco LLC Makes New $4.42 Million Investment in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Man Group plc Buys New Shares in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

Formula Growth Ltd. Makes New $1.15 Million Investment in Vericel Corporation $VCEL

August 28, 2026 | marketbeat.com

Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 4,500 Shares

August 1, 2026 | insidertrades.com

Vericel Corporation 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

July 30, 2026 | zacks.com

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

July 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OPT, KOD, AGIO, and VCEL Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$32.58 -0.32 (-0.97%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$32.60 +0.02 (+0.06%)

As of 09/25/2026 07:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Kodiak Sciences NASDAQ:KOD

$32.35 -0.87 (-2.62%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$35.32 +2.97 (+9.19%)

As of 09/25/2026 07:59 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Opthea NASDAQ:OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Vericel NASDAQ:VCEL

$39.71 +0.41 (+1.04%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$39.81 +0.10 (+0.25%)

As of 09/25/2026 07:58 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, KOD, AGIO, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, KOD, AGIO, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, KOD, AGIO, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, KOD, AGIO, and VCEL Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Kodiak Sciences NASDAQ:KOD

Opthea NASDAQ:OPT

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, KOD, AGIO, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, KOD, AGIO, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, KOD, AGIO, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, KOD, AGIO, and VCEL Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Kodiak Sciences NASDAQ:KOD

Opthea NASDAQ:OPT

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools